Healthcare Industry News: PHOENIX
News Release - February 12, 2008
Sapphire Therapeutics Promotes Suzan Allen to Vice President Clinical Operations
BRIDGEWATER, NJ--(Healthcare Sales & Marketing Network)--Feb 12, 2008 -- Sapphire Therapeutics, Inc., a private biopharmaceutical company that develops compounds acting within the ghrelin pathway as treatments for metabolic, oncologic, and gastrointestinal diseases, today announced the promotion of Suzan Allen to Vice President Clinical Operations."With two drugs in clinical development and a new program in obesity, clinical operations has become more important than ever to Sapphire," said William J Polvino, MD, President and CEO of Sapphire. "Therefore, I am very pleased to announce Suzan's promotion as she continues to lead our clinical operations team in conducting several large clinical studies simultaneously, especially as we launch registration trials."
Suzan Allen joined Sapphire in early 2007 as Executive Director, Clinical Operations. Prior to joining Sapphire, she had 13 years experience as a clinical consultant, providing pharmaceutical clients with clinical development operational support for EU and US clinical trials (Phases I-IV). Her consulting services included all aspects of Good Clinical Practice (compliance, monitoring, QA/QC, training and SOP development).
Suzan was previously Senior Director, Clinical Projects for The Hardardt Group in New Jersey, and prior to that, Clinical Project Manager for Harris Laboratories, and Laboratory Administrator at St. Luke's Health Systems in PHOENIX, Arizona. She began her clinical operations career in Texas, with a BA&S and MS from West Texas State University, followed by laboratory positions at Northwest Texas Hospital and Texas Tech University Health Science Center.
About Sapphire Therapeutics
Sapphire is a private biopharmaceutical company that develops promising small-molecule ghrelin mimetics to treat metabolic, oncologic, and gastrointestinal diseases for which existing therapies are limited or marginally effective. The company's pipeline consists of first-in-class, composition-of-matter protected compounds acting within the ghrelin pathway.
For more information, please visit Sapphire Therapeutics' web site at www.sapphirethera.com.
Source: Sapphire Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
